ACTR-48. FEASIBILITY OF DISCONTINUATION OF ADJUVANT TEMOZOLOMIDE AFTER 12 CYCLES REMAINING WITHOUT PROGRESSION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

BACKGROUND: Standard of care for newly diagnosed glioblastoma (GBM) has been chemoradiotherapy with concomitant and adjuvant temozolomide (TMZ) (Stupp regimen). Optimal number of adjuvant TMZ cycles, however, has not been well established yet, although the pivotal trial used 6 cycles. In routine pra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Nagane, Motoo, Kobayashi, Keiichi, Saito, Kuniaki, Shimizu, Saki, Suematsu, Shinya, Kume, Satoshi, Okamura, Yuma, Shiokawa, Yoshiaki
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216401/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.080
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados